N/A N=152 Olanzapine Versus Placebo for Outpatients With Anorexia Nervosa
Anorexia Nervosa
Primary: Rate of Weight Change — 0.095; 0.260 kg/m^2 per month
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=33 Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic
Schizophrenia · Cognition · Cigarette Smoking
Primary: Change From Baseline in Cigarette Craving — 14.40; 11.00 Units on QSU-Brief Scale
Phase 3 N=60 Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone
Opiate Dependence · Heroin Dependence
Primary: Treatment Retention — 24; 20; 17; 14 Participants
Phase 3 N=291 An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
Schizophrenia
Primary: Number and Percentage of Subjects With Treatment-emergent Adverse Events (TEAEs) — 21; 94 Participants
N/A N=36 Sedatives' Effects on Neurological Function in Patients With Eloquent Area Glioma
Glioma
Primary: Task Completing Time Change Between Sedation and Baseline Measured by 9-hole Peg Test — 27.8; 19.1; 54.3; 21.4 seconds — p=<0.01
Phase 3 N=443 Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms
Breast Cancer · Gynecologic Cancer
Primary: Alleviation of the Most Bothersome Vaginal Symptom (Vaginal Dryness or Dyspareunia) Over 12 Weeks — -2; -2; -1 change in units on a scale — p=0.08
Phase 3 N=450 Contraceptive Effectiveness and Safety of the SILCS Diaphragm
Contraception
Primary: Percent Probability of Pregnancy Among Users of the SILCS Diaphragm Used With Contraceptive Gel Over 6 Months of Typical Use — 12.5; 9.6 percent probability
N/A N=51 Effectiveness and Safety Study of the Dexcom G4 Platinum With Modified Algorithm
Diabetes Mellitus
Primary: The Percentage of Agreement of the Continuous Glucose Monitoring System Glucose Values Comparing to a Laboratory Reference, Yellow Sprint Instrument (YSI) Measurement…
N/A N=19 A Transparent Elasticized Adhesive Occlusive Compression Bandage for Use as an Arterial Tourniquet
Hemorrhage · Vascular Injury
Primary: Radiologist Limb Occlusion Assessment — 19; 18; 8; 8 Participants — p=0.002
Phase 2 N=89 Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
Myelodysplastic Syndrome · Hodgkin's Lymphoma · Non-Hodgkin's Disease
Primary: Percentage of Participants With Grade II-IV Acute Graft Versus Host Disease (GVHD) — 42; 38 percentage of participants
Phase 2 N=33 Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
Small Intestine Adenocarcinoma · Recurrent Small Intestine Cancer
Primary: Confirmed Tumor Response Rate (Proportion of Participants With Complete Response) — .38 proportion of patients
Phase 4 N=72 Intra-operative Digital vs. Standard Mammography
Breast Cancer
Primary: Comparison of Operative Time Savings — 48.5; 54; 68; 74 Minutes — p=0.716
Phase 2 N=58 Combined Spinal-Epidural Temperature and Duration of Action
Pain
Primary: Time — 74; 81 minutes
N/A N=330 PRIDE: Preventing Respiratory Illnesses During Childhood Study
Tobacco Smoke Pollution
Primary: Air Nicotine Levels — 1.17; 0.58; 0.71; 0.51 mg/m^3
Phase 3 N=213 Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
Breast Cancer · Cognitive/Functional Effects · Lung Cancer
Primary: Neurocognitive Progression as Measured by the Number of Participants With Cognitive Deterioration by 3 Months — 40; 44 Participants — p=<0.001